PMID- 23308402
OWN - NLM
STAT- MEDLINE
DCOM- 20140115
LR  - 20211021
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Print)
IS  - 1461-1457 (Linking)
VI  - 16
IP  - 6
DP  - 2013 Jul
TI  - Cognitive impairments from developmental exposure to serotonergic drugs: 
      citalopram and MDMA.
PG  - 1383-94
LID - 10.1017/S1461145712001447 [doi]
AB  - We previously showed that developmental 3,4-methylenedioxymethamphetamine (MDMA) 
      treatment induces long-term spatial and egocentric learning and memory deficits 
      and serotonin (5-HT) reductions. During brain development, 5-HT is a neurotrophic 
      factor influencing neurogenesis, synaptogenesis, migration, and target field 
      organization. MDMA (10 mg/kg x 4/d at 2 h intervals) given on post-natal day (PD) 
      11-20 in rats (a period of limbic system development that approximates human 
      third trimester brain development) induces 50% reductions in 5-HT during 
      treatment and 20% reductions when assessed as adults. To determine whether the 
      5-HT reduction is responsible for the cognitive deficits, we used citalopram 
      (Cit) pretreatment to inhibit the effects of MDMA on 5-HT reuptake in a companion 
      study. Cit attenuated MDMA-induced 5-HT reductions by 50% (Schaefer et al., 
      2012). Here we tested whether Cit (5 or 7.5 mg/kg x 2/d) pretreatment attenuates 
      the cognitive effects of MDMA. Within each litter, different offspring were 
      treated on PD11-20 with saline (Sal) + MDMA, Cit + MDMA, Cit + Sal or Sal + Sal. 
      Neither spatial nor egocentric learning/memory was improved by Cit pretreatment. 
      Unexpectedly, Cit + Sal (at both doses) produced spatial and egocentric learning 
      deficits as severe as those caused by Sal + MDMA. These are the first data 
      showing cognitive deficits resulting from developmental exposure to a selective 
      serotonin reuptake inhibitor. These data indicate the need for further research 
      on the long-term safety of antidepressants during pregnancy.
FAU - Schaefer, Tori L
AU  - Schaefer TL
AD  - Division of Child Neurology, Department of Pediatrics, Cincinnati Children's 
      Research Foundation and University of Cincinnati College of Medicine, Cincinnati, 
      OH 45229-3039, USA.
FAU - Grace, Curtis E
AU  - Grace CE
FAU - Braun, Amanda A
AU  - Braun AA
FAU - Amos-Kroohs, Robyn M
AU  - Amos-Kroohs RM
FAU - Graham, Devon L
AU  - Graham DL
FAU - Skelton, Matthew R
AU  - Skelton MR
FAU - Williams, Michael T
AU  - Williams MT
FAU - Vorhees, Charles V
AU  - Vorhees CV
LA  - eng
GR  - DA21394/DA/NIDA NIH HHS/United States
GR  - K01 DA014269/DA/NIDA NIH HHS/United States
GR  - R01 DA021394/DA/NIDA NIH HHS/United States
GR  - T32 ES007051/ES/NIEHS NIH HHS/United States
GR  - ES007051/ES/NIEHS NIH HHS/United States
GR  - DA014269/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130111
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Serotonin Agents)
RN  - 0DHU5B8D6V (Citalopram)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Body Weight/drug effects
MH  - Citalopram/*toxicity
MH  - Cognition Disorders/*chemically induced/physiopathology
MH  - Disease Models, Animal
MH  - Female
MH  - Locomotion/drug effects
MH  - Male
MH  - Maze Learning/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*toxicity
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin Agents/*toxicity
MH  - Swimming/psychology
PMC - PMC4594864
MID - NIHMS724401
EDAT- 2013/01/12 06:00
MHDA- 2014/01/16 06:00
PMCR- 2015/10/06
CRDT- 2013/01/12 06:00
PHST- 2013/01/12 06:00 [entrez]
PHST- 2013/01/12 06:00 [pubmed]
PHST- 2014/01/16 06:00 [medline]
PHST- 2015/10/06 00:00 [pmc-release]
AID - S1461145712001447 [pii]
AID - 10.1017/S1461145712001447 [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2013 Jul;16(6):1383-94. doi: 
      10.1017/S1461145712001447. Epub 2013 Jan 11.